Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis
Provided By GlobeNewswire
Last update: Jul 7, 2025
– National Footprint of NEXICART-2 Trial Sites Expanded –
– On track for first Biologics License Application (BLA) approved cell therapy in unaddressed orphan indication –
Read more at globenewswire.com
